Modified FGF-21 for NASH Treatment via Pro-C3 Biomarker Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Nonalcoholic Steatohepatitis (NASH) lack effective pharmacological therapies, and there is a need for methods to monitor the progression and abatement of the disease.
Innovation Solution
Administration of a modified Fibroblast Growth Factor 21 (FGF-21) to patients with specific serum Pro-C3 threshold levels, along with monitoring responsiveness through Pro-C3 level changes in blood samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modified FGF-21 is administered to treat NASH, then therapeutic efficacy is improved (reduction in liver stiffness and hepatic fat fraction), but treatment cost and complexity increase due to biomarker monitoring requirements
Solution Approach 1:
The patent performs preliminary action by measuring Pro-C3 biomarker levels before initiating FGF-21 treatment to identify patients who will respond therapeutically. This preliminary screening ensures that only suitable candidates receive the treatment, improving overall therapeutic efficacy while avoiding unnecessary treatment complexity for non-responders.
Solution Approach 2:
The patent implements feedback mechanisms by monitoring Pro-C3 levels and treatment response (liver stiffness, hepatic fat fraction) to adjust and optimize FGF-21 dosing regimens. This feedback loop ensures maintained therapeutic efficacy while allowing simplification of treatment protocols based on observed patient responses.
2Measurement precision
If Pro-C3 biomarker monitoring is implemented to identify suitable patients, then treatment selection accuracy is improved, but diagnostic complexity and time increase
Solution Approach 1:
The patent applies segmentation by dividing the patient population into distinct groups based on Pro-C3 biomarker thresholds (e.g., patients with Pro-C3 >10 ng/mL versus those with lower levels). This segmentation enables precise identification of treatment candidates without requiring complex diagnostic workups for all patients, thereby improving selection accuracy while managing diagnostic complexity.
Solution Approach 2:
The patent utilizes parameter changes by establishing specific Pro-C3 concentration thresholds (e.g., 10 ng/mL, 20 ng/mL) as decision criteria for treatment eligibility. By converting a continuous biomarker measurement into discrete threshold-based categories, the patent simplifies the diagnostic decision-making process while maintaining measurement precision for patient stratification.
3Reliability
If FGF-21 treatment is administered based on Pro-C3 threshold levels, then treatment effectiveness is improved, but loss of time for biomarker determination increases
Solution Approach 1:
The patent performs preliminary Pro-C3 biomarker determination before treatment initiation to quickly identify eligible patients. By conducting this single preliminary measurement rather than repeated monitoring during the decision-making process, the patent minimizes time loss while ensuring treatment effectiveness is based on accurate biomarker status.
Solution Approach 2:
The patent enables self-service by using readily available blood sampling and established Pro-C3 assay methods that can be performed in routine clinical laboratories without specialized equipment or procedures. This approach reduces time investment for biomarker determination while maintaining treatment effectiveness through reliable biomarker assessment.
Data Source
AI summary
Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.